|Videos|July 24, 2023
Safety Profile of S1P Receptor Modulators for Multiple Sclerosis
Author(s)Krzysztof Selmaj, MD, PhD
Krzysztof Selmaj, MD, PhD, discusses the side effects of sphinogine-1-phospate (S1P) receptor modulators, highlighting particular adverse events clinicians should be aware of when treating multiple sclerosis (MS).
Advertisement
Episodes in this series
Advertisement
Related to this article
Here's some of what is coming soon to NeurologyLive® this week.
The professor of neurology at the University of Lyon and 2026 Rachel Horne Prize Winner discussed pregnancy counseling, therapeutic inertia, and overlooked women's health issues in multiple sclerosis.
The FDA accepted fenebrutinib's new drug application under priority review for relapsing and primary progressive MS, based on 3 phase 3 trials comparing the BTK inhibitor with teriflunomide and ocrelizumab.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Christen Kutz, PhD, PA-C, on What Real-World Data Reveal About Treatment Transitions to Nipocalimab in Generalized Myasthenia Gravis
2
Emerging Advances in Parkinson Disease Ahead of MDS 2026: Benjamin Walter, MD, MBA
3
From Cord Blood to Cannabinoids: 7 Agents to Watch in Cerebral Palsy
4
LRRK2 Inhibitor BIIB122 Fails to Slow Early-Stage Parkinson Disease
5